Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir by unknown
REVIEW ARTICLE
Drug–Drug Interactions with the NS3/4A Protease Inhibitor
Simeprevir
Sivi Ouwerkerk-Mahadevan1 • Jan Snoeys1 • Monika Peeters2 •
Maria Beumont-Mauviel2 • Alexandru Simion2
Published online: 9 September 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Simeprevir is an NS3/4A protease inhibitor
approved for the treatment of hepatitis C infection, as a
component of combination therapy. Simeprevir is metab-
olized by the cytochrome P450 (CYP) system, primarily
CYP3A, and is a substrate for several drug transporters,
including the organic anion transporting polypeptides
(OATPs). It is susceptible to metabolic drug–drug inter-
actions with drugs that are moderate or strong CYP3A
inhibitors (e.g. ritonavir and erythromycin) or CYP3A
inducers (e.g. rifampin and efavirenz); coadministration of
these drugs may increase or decrease plasma concentra-
tions of simeprevir, respectively, and should be avoided.
Clinical studies have shown that simeprevir is a mild
inhibitor of CYP1A2 and intestinal CYP3A but does not
inhibit hepatic CYP3A. The effects of simeprevir on these
enzymes are of clinical relevance only for narrow-thera-
peutic-index drugs that are metabolized solely by these
enzymes (e.g. oral midazolam). Simeprevir does not have a
clinically relevant effect on the pharmacokinetics of rilpi-
virine, tacrolimus, oral contraceptives and several other
drugs metabolized by CYP enzymes. Simeprevir is a sub-
strate and inhibitor of the transporters P-glycoprotein (P-
gp), breast cancer resistance protein (BCRP) and
OATP1B1/3. Cyclosporine is an inhibitor of OATP1B1/3,
BCRP and P-gp, and a mild inhibitor of CYP3A; cyclos-
porine causes a significant increase in simeprevir plasma
concentrations, and coadministration is not recommended.
Clinical studies have demonstrated increases in
coadministered drug concentrations for drugs that are
substrates of the OATP1B1/3, BRCP (e.g. rosuvastatin)
and P-gp (e.g. digoxin) transporters; these drugs should be
administered with dose titration and or/close monitoring.
Key Points
Simeprevir is primarily metabolized by cytochrome
P450 (CYP) 3A, and coadministration of drugs that
are moderate or strong CYP3A inducers or inhibitors
should be avoided.
Simeprevir is a mild intestinal, but not hepatic,
CYP3A inhibitor and is an inhibitor and substrate of
P-glycoprotein, organic anion transporting
polypeptide and breast cancer resistance protein
transporters.
Simeprevir can be safely coadministered with a wide
variety of drugs.
1 Introduction
Hepatitis C virus (HCV) infection affects an estimated 170
million people worldwide and is a major source of mor-
bidity and mortality [1]. Prior to the approval of direct-
acting antiviral agents in 2011, the standard of care was
pegylated interferon (PegIFN) and ribavirin (RBV) com-
bination therapy, which induced a sustained virological
response (SVR) in C80 % of patients with HCV genotypes
2 and 3 but in only *40–50 % of those with HCV
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genotype 1 [2]. The significantly improved SVR rates
observed with direct-acting antiviral agents has led to the
substantial evolution of HCV treatment paradigms [3].
Simeprevir is an NS3/4A protease inhibitor approved for
the treatment of chronic HCV infection, as a component of
combination therapy [4, 5]. The 2014 American Associa-
tion for the Study of Liver Diseases (AASLD) and Infec-
tious Disease Society of America (IDSA) guidelines now
include a recommendation for use of simeprevir, in com-
bination with sofosbuvir (±RBV), for the treatment of
HCV genotype 1 infection in treatment-experienced
patients and for treatment-naı¨ve patients who are ineligible
for interferon (IFN); simeprevir is also recommended as
part of several alternative treatment regimens, including
those for HCV genotype 4 and HIV co-infection [3].
Simeprevir has demonstrated high SVR rates in patients
with HCV genotype 1 infection during phase II and III
trials [4–10]. In the phase II COSMOS trial, combination
therapy with simeprevir and sofosbuvir (±RBV), an IFN-
free regimen, was demonstrated to have an SVR 12 weeks
after the planned end of treatment (SVR12) of 92–94 % in
treatment-naı¨ve and treatment-experienced subjects
([60 % Caucasian subjects in each study group) [10]. In
the phase III QUEST (QUEST-1 and QUEST-2) and
PROMISE trials, combination therapy with simeprevir plus
PegIFN and RBV demonstrated SVR12 rates of 80 % in
treatment-naı¨ve subjects and 79.2 % in prior relapser
subjects ([90 % Caucasian subjects) [4, 7, 9, 11].
Simeprevir has also shown efficacy in the treatment of
subjects with HCV genotype 1 and HIV co-infection and in
subjects with HCV genotype 4 when used in combination
with PegIFN and RBV [12, 13].
The safety of simeprevir has also been demonstrated in
phase II and III trials [4, 7–10, 14]. In the COSMOS trial,
which evaluated simeprevir plus sofosbuvir, \5 % of
subjects experienced grade 3–4 adverse events, excluding
subjects with increased blood amylase levels (reported in
4–7 % of each study group; no cases of pancreatitis were
reported) [10]. In this trial, the most common adverse
events were fatigue, headache and nausea. Pooled results
from three phase III trials that evaluated simeprevir plus
IFN and RBV (QUEST-1, QUEST-2 and PROMISE)
demonstrated similar rates of grade 3–4 adverse events
with simeprevir plus PegIFN and RBV compared with
PegIFN and RBV alone (23 and 25 %, respectively) [4, 7,
9, 11]. Adverse events occurring with C3 % frequency
with the addition of simeprevir in comparison with
PegIFN and RBV alone included rash (photosensitivity),
pruritus, nausea, myalgia and dyspnoea. Of note, transient
increases in bilirubin were observed in the phase II
COSMOS trial and in the phase III QUEST-1, QUEST-2
and PROMISE trials [4, 7, 9, 10]. These were most
prominent in the setting of simeprevir and RBV
coadministration, and can be explained by the inhibition
of organic anion transporting polypeptide (OATP) 1B1
and multidrug resistance-associated protein (MRP) 2
hepatic bilirubin transporters by simeprevir, in combina-
tion with elevated bilirubin levels as a result of RBV-
associated red blood cell haemolysis [10].
Potential drug–drug interactions among these relatively
new direct-acting antiviral agents, or between these agents
and other therapies, are important to evaluate because of
the possibility of coadministration [15]. This article
reviews the clinical pharmacokinetics and drug–drug
interaction data on simeprevir.
2 Clinical Pharmacokinetics of Simeprevir
Simeprevir is orally bioavailable, with maximum plasma
concentration (Cmax) values being observed approximately
4–6 h postdose [16]. The area under the concentration-time
curve (AUC) was shown to be increased from 61 and 69 %
when simeprevir was administered with a high-fat/high-
caloric and normal-caloric breakfast, respectively; there-
fore, it is recommended that simeprevir be administered
with food [17].
Simeprevir is extensively bound to plasma proteins
([99.9 %), largely to albumin; binding is not significantly
different in renal or hepatic impairment [11, 18, 19].
In vitro data suggest that OATPs, including OATP1B1 and
OATP1B3, mediate hepatic uptake of simeprevir [20].
Elimination occurs mainly via biliary excretion [20].
Simeprevir is metabolized by the liver. In vitro studies
suggest that metabolism occurs primarily through the CYP
enzyme, CYP3A [21]. In addition to being a substrate for
CYP3A and OATPs, simeprevir is a substrate for several
efflux transporters, including MRP2, P-gp and breast can-
cer resistance protein (BCRP; on the basis of in vitro
studies; data on file) [20].
In clinical studies, the mean terminal elimination half-
life was shown to be approximately 10–13 h in subjects
without HCV infection and approximately 41 h in HCV-
infected subjects [16]. The observed extension of the
simeprevir half-life in HCV-infected subjects compared
with healthy participants may be due to the presence of
HCV infection in combination with the consequences of
the underlying liver disease; however, the number of HCV-
infected subjects evaluated was relatively small (n = 6).
Once-daily dosing is recommended for HCV-infected
patients [17]; with this regimen, steady state is attained in
7 days [11].
Other pharmacokinetic characteristics of simeprevir
include the following: Cmax and AUC increased more than
dose proportionally following administration of repeated
doses of simeprevir (doses between 75 mg and 200 mg
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daily) [11, 16]. The plasma exposures (Cmax and AUC)
were similar with simeprevir in combination with PegIFN-
alfa and RBV in comparison with simeprevir alone [11].
The AUC value was 2–3 times higher in subjects infected
with HCV than in uninfected subjects, a phenomenon that
has been reported previously with selected protease inhi-
bitors used to treat HIV infection, oral midazolam and
other HCV protease inhibitors [22–24]; however, as studies
comparing drug pharmacokinetics in HIV-1-infected sub-
jects versus healthy participants have demonstrated, phys-
iological changes that accompany infection can have a
variety of effects on individual metabolic enzymes,
including those in the same family [23, 25]. Altered
pharmacokinetics may result from differences in the
numbers of functional hepatocytes, transporter expression
and/or CYP expression in HCV-infected individuals com-
pared with individuals without HCV infection. Subclinical
liver disease could also potentially contribute to differences
in simeprevir pharmacokinetics in HCV-infected individ-
uals compared with healthy controls.
Simeprevir exposure was mildly increased in subjects
with severe renal impairment compared with subjects with
normal renal function [the AUC from 0 to 24 h (AUC24h)
and Cmax increased 62 and 34 %, respectively] [18]; no
dose adjustment is required in patients with severe renal
impairment [11]. Simeprevir exposure was also increased
by approximately 2-fold in non-HCV-infected subjects
with moderate hepatic impairment compared with matched
healthy controls; exposure was further increased in non-
HCV-infected subjects with severe hepatic dysfunction
(approximately a 2-fold increase in exposure in severe
compared with moderate hepatic impairment) [19]. As a
result, no dose recommendation can be given for patients
with moderate or severe hepatic impairment [11].
Simeprevir has a wide therapeutic index, with no clear
relationships between plasma exposure and efficacy and
safety parameters. In general, there were no consistent
relationships between simeprevir exposure and virological
response parameters in phase II and III studies at dose
ranges between 75 and 150 mg.
3 Drug Interactions Caused by Simeprevir
as an Inhibitor or Inducer
In vitro studies suggest that simeprevir is a moderate
inhibitor of CYP2A6, CYP2C8 and CYP2D6, and a weak
inhibitor of CYP2C19 and CYP3A [11]; therefore, clinical
studies were performed to investigate the potential of
simeprevir to alter the pharmacokinetics of drugs metabo-
lized by these CYP enzymes. In addition, in vitro studies
conducted to assess the cause of transient bilirubin eleva-
tions that were observed in clinical trials suggested that
simeprevir is also an inhibitor of the transporters
OATP1B1, MRP2, bile salt export pump (BSEP), P-gp and
BCRP [11, 20]. In vitro studies demonstrated no clinically
relevant inhibition of cathepsin A (data on file).
3.1 Metabolic Drug–Drug Interactions
3.1.1 Drugs Metabolized by CYP Enzymes
The effect of simeprevir on the CYP system was clinically
evaluated in a phase I, two-period, open-label, randomized,
crossover trial, which utilized five representative CYP
probes [21]. In this trial, 16 healthy subjects (five male)
received oral midazolam (0.075 mg/kg; a probe for
intestinal CYP3A) and a drug cocktail consisting of intra-
venous midazolam (0.025 mg/kg; a probe for hepatic
CYP3A), warfarin (10 mg; a probe for CYP2C9), caffeine
(150 mg; a probe for CYP1A2), omeprazole (40 mg; a
probe for CYP2C19) and dextromethorphan (30 mg; a
probe for CYP2D6) alone or in combination with 150 mg
of simeprevir under fed conditions. All drugs were
administered orally except for midazolam, which was
administered both orally (alone) and intravenously (as part
of the drug cocktail) to differentiate between intestinal and
hepatic CYP3A activity. The presence of simeprevir
resulted in increased exposure to oral midazolam (the Cmax
and AUC from time zero to the time of the last measurable
concentration (AUClast) increased by 1.31- and 1.45-fold,
respectively) and caffeine (the Cmax and AUClast increased
by 1.12- and 1.26-fold, respectively; see Table 1).
Simeprevir coadministration also resulted in increased
exposure to omeprazole (the Cmax and AUClast increased
by 1.14- and 1.21-fold, respectively), and little to no
change in exposure to dextromethorphan (the Cmax and
AUClast increased by 1.21- and 1.08-fold, respectively) and
warfarin (the Cmax and AUClast increased by 1.00- and
1.04-fold, respectively). An increased parent drug to
metabolite ratio of 1.31 was seen for oral midazolam,
suggesting that the increased midazolam exposure was due
to mild intestinal CYP3A inhibition; this increase was not
seen for intravenous midazolam, suggesting no effect on
CYP3A hepatic metabolism. Additionally, there was a
1.34-fold increase in the parent drug to metabolite ratio of
caffeine, suggesting mild CYP1A2 inhibition by simepre-
vir. The parent compound to metabolite ratios of warfarin,
omeprazole and dextromethorphan were similar with and
without administration of simeprevir, suggesting no rele-
vant clinical interaction of simeprevir with CYP2C9,
CYP2C19 and CYP2D6.
CYP1A2 substrates (e.g. caffeine), CYP2C9 substrates
(e.g. warfarin) and CYP2C19 substrates (e.g. omeprazole)
may be coadministered with simeprevir without dose adjust-
ments [21]. Exposure of CYP3A substrates may be mildly
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increased (31 % for oral midazolam) because of inhibition of
intestinal CYP3A by simeprevir; therefore, caution should be
exercised when simeprevir is coadministered with CYP3A
substrates with a narrow therapeutic index.
3.1.1.1 Rilpivirine Rilpivirine, a non-nucleoside reverse
transcriptase inhibitor (NNRTI) used in the treatment of
HIV, is a substrate of CYP3A. In an open-label, random-
ized, three-period crossover study with a washout period of
at least 14 days, 24 healthy subjects (12 male) received
simeprevir (150 mg once daily), rilpivirine (25 mg once
daily) or simeprevir (150 mg once daily) plus rilpivirine
(25 mg once daily) for 10 days under fed conditions [26].
The Cmax of simeprevir increased by 1.10-fold; the mini-
mum plasma concentration (Cmin) and AUC24h were
unchanged (Table 2). The mean Cmin of rilpivirine
increased by 1.25-fold; the Cmin and AUC24h were
unchanged (Table 3; see also Table 4 for a concise sum-
mary of data included in Tables 2 and 3). Neither
simeprevir exposure nor rilpivirine exposure was affected
to a clinically relevant degree; therefore, no dose adjust-
ment is required for coadministration of these drugs.
3.1.1.2 Ethinylestradiol and Norethin-
drone Ethinylestradiol and norethindrone are commonly
used oral contraceptives. RBV, which can be used in
combination therapy with simeprevir, is known to be ter-
atogenic, and effective methods of contraception are
required for women of childbearing potential who are
taking RBV [27]; therefore, many patients will be receiving
oral contraceptive therapy while on simeprevir. The
metabolism of ethinylestradiol occurs predominately
through CYP3A and CYP2C9 [28]. CYP3A is also
involved in the metabolism of norethindrone [29]. Inter-
actions between simeprevir and ethinylestradiol/norethin-
drone were evaluated in an open-label study of 18 healthy
female subjects [30]. Subjects received ethinylestradiol/
norethindrone (35 lg/1 mg) for two consecutive 28-day
oral contraceptive cycles (21 days of the drug, followed by
a 7-day drug-free period). During the second cycle (days
29–56), subjects also received simeprevir (150 mg once
daily) for the last 10 days of ethinylestradiol/norethindrone
treatment (days 40–49; all treatments were taken under fed
conditions). The Cmin and AUC24h for ethinylestradiol were
similar with coadministration of simeprevir in comparison
with ethinylestradiol/norethindrone alone [although the
90 % confidence interval (CI) for the AUC24h ratio of test
to reference did not include 1]; the Cmax was 18 % higher
with coadministration (Table 3). The Cmax and AUC24h
values for norethindrone were similar with coadministra-
tion of simeprevir in comparison with ethinylestradiol/
norethindrone alone (although the 90 % CI for the AUC24h
ratio of test to reference did not include 1); the Cmin was
24 % higher with coadministration. These differences are
unlikely to be clinically relevant. Serum hormone levels for
progesterone, follicle-stimulating hormone and luteinizing
hormone were also evaluated in this study; coadministra-
tion of simeprevir did not yield differences in these hor-
mone levels in comparison with ethinylestradiol/
norethindrone alone. Therefore, ethinylestradiol/norethin-
drone may be used in combination with simeprevir without
dose adjustment.





a Parent to metabolite ratio
Midazolam: oralb CYP3A (intestinal) 1.31 (1.19–1.45) 1.45 (1.35–1.57) 1.31 (1.21–1.42)
Midazolam: intravenousb CYP3A (hepatic) 0.78 (0.52–1.17) 1.10 (0.95–1.26) 1.01 (0.86–1.18)
S-warfarinc CYP2C9 1.00 (0.94–1.06) 1.04 (1.00–1.07) 0.98 (0.86–1.12)
Caffeined CYP1A2 1.12 (1.06–1.19) 1.26 (1.21–1.32) 1.34 (1.26–1.42)
Omeprazolee CYP2C19 1.14 (0.93–1.39) 1.21 (1.00–1.46) 0.98 (0.85–1.12)
Dextromethorphanf CYP2D6 1.21 (0.93–1.57) 1.08 (0.87–1.35) 0.99 (0.80–1.23)
AUClast area under the concentration-time curve from time zero to the time of the last measurable concentration, CI confidence interval,
Cmax maximum plasma concentration, CYP cytochrome P450
a The values represent the least squares mean ratio (and 90 % CI) of each PK parameter of the cytochrome probe substrate coadministered with
simeprevir versus without simeprevir
b The metabolite is 1-OH-midazolam
c The metabolite is 7-OH-S-warfarin
d The metabolite is paraxanthine
e The metabolite is 5-OH-omeprazole
f The metabolite is dextrorphan
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Table 2 Effects of coadministered drugs on the pharmacokinetics (PK) of simeprevir (multiple dosing)
Coadministered drug Effect on PKa PK parameters (ratio of simeprevir coadministration to simeprevir alone)b
Cmax AUC24h Cmin
Erythromycin : 4.53 (3.91–5.25) 7.47 (6.41–8.70) 12.74 (10.19–15.93)
Rifampin ; 1.31 (1.03–1.66) 0.52 (0.41–0.67) 0.08 (0.06–0.11)
Escitalopram ; 0.80 (0.71–0.89) 0.75 (0.68–0.83) 0.68 (0.59–0.79)
Ritonavir : 4.70 (3.84–5.76) 7.18 (5.63–9.15) 14.35 (10.29–20.01)
Darunavir/ritonavirc : 1.79 (1.55–2.06) 2.59 (2.15–3.11) 4.58 (3.54–5.92)
Efavirenz ; 0.49 (0.44–0.54) 0.29 (0.26–0.33) 0.09 (0.08–0.12)
Rilpivirine $ 1.10 (0.97–1.26) 1.06 (0.94–1.19) 0.96 (0.83–1.11)
Tenofovir ; 0.85 (0.73–0.99) 0.86 (0.76–0.98) 0.93 (0.78–1.11)
Raltegravir $ 0.93 (0.85–1.02) 0.89 (0.81–0.98) 0.86 (0.75–0.98)
AUC24h area under the concentration-time curve from 0 to 24 h, CI confidence interval, Cmax maximum plasma concentration, Cmin minimum
plasma concentration
a The arrows signify the effects on the PK of simeprevir according to the change in the mean ratio of the AUC24h: an increase (:), decrease (;) or
no change ($; if the 90 % CI is within the range of 0.80–1.25)
b The values represent the least squares means (90 % CIs) of coadministered simeprevir compared with simeprevir alone
c The dose of simeprevir was 150 mg once daily when it was administered alone, compared with 50 mg when it was coadministered with
darunavir/ritonavir
Table 3 Effects of simeprevir on the pharmacokinetics (PK) of coadministered drugs
Coadministered drug Effect on PKa PK parameters (ratio of simeprevir coadministration to administration alone)b
Cmax AUC24h Cmin
Erythromycin : 1.59 (1.23–2.05) 1.90 (1.53–2.36) 3.08 (2.54–3.73)
Rifampin $ 0.92 (0.80–1.07) 1.00 (0.93–1.08) NA
Escitalopram $ 1.03 (0.99–1.07) 1.00 (0.97–1.03) 1.00 (0.95–1.05)
Ethinylestradiol $ 1.18 (1.09–1.27) 1.12 (1.05–1.20) 1.00 (0.89–1.13)
Norethindrone $ 1.06 (0.99–1.14) 1.15 (1.08–1.22) 1.24 (1.13–1.35)
Atorvastatin : 1.70 (1.42–2.04) 2.12 (1.72–2.62) NA
Simvastatin : 1.46 (1.17–1.82) 1.51 (1.32–1.73) NA
Rosuvastatin : 3.17 (2.57–3.91) 2.81 (2.34–3.37) NA
Digoxin : 1.31 (1.14–1.51) 1.39 (1.16–1.67) NA
Cyclosporine : 1.16 (1.07–1.26) 1.19 (1.13–1.26) NA
Tacrolimus ; 0.76 (0.65–0.90) 0.83 (0.59–1.16) NA
Methadone $ 1.03 (0.97–1.09) 0.99 (0.91–1.09) 1.02 (0.93–1.12)
Ritonavir : 1.23 (1.14–1.32) 1.32 (1.25–1.40) 1.44 (1.30–1.61)
Darunavir : 1.04 (0.99–1.10) 1.18 (1.11–1.25) 1.31 (1.13–1.52)
Efavirenz $ 0.97 (0.89–1.06) 0.90 (0.85–0.95) 0.87 (0.81–0.93)
Rilpivirine $ 1.04 (0.95–1.13) 1.12 (1.05–1.19) 1.25 (1.16–1.35)
Tenofovir $ 1.19 (1.10–1.30) 1.18 (1.13–1.24) 1.24 (1.15–1.33)
Raltegravir : 1.03 (0.78–1.36) 1.08 (0.85–1.38) 1.14 (0.97–1.36)
AUC24h area under the concentration-time curve from 0 to 24 h, CI confidence interval, Cmax maximum plasma concentration, Cmin minimum
plasma concentration, NA not available
a The arrows signify the effects on the PK of the coadministered drug according to the change in the mean ratio of the AUC24h: an increase (:),
decrease (;) or no change ($; if the 90 % CI is within the range of 0.80–1.25)
b The values represent the least squares means (90 % CIs) of coadministration with simeprevir in comparison with the coadministered drug used
alone
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3.1.1.3 Cyclosporine/Tacrolimus Cyclosporine and tacro-
limus are both immunosuppressants used to prolong allo-
geneic transplant survival, including liver transplants [31].
Both are substrates for and mild inhibitors of CYP3A, and
are substrates for P-gp. Cyclosporine is also an inhibitor of
P-gp, OATP1B1 and OATP1B3 [31]. Drug–drug interac-
tions between simeprevir and cyclosporine or tacrolimus
are important, as coadministration may occur in patients
with HCV in the setting of liver transplantation. In a two-
panel, randomized, open-label, two-period crossover study,
14 healthy subjects (eight male) received cyclosporine
(100 mg single dose) or simeprevir (150 mg once daily on
days 1–10) plus cyclosporine (100 mg single dose on day
7), and 14 healthy subjects (seven male) received tacroli-
mus (2 mg single dose) or simeprevir (150 mg once daily
on days 1–12) plus tacrolimus (2 mg single dose on day 7)
[32]. Simeprevir alone was administered under fed condi-
tions; all other treatments were administered under fasting
conditions. For cyclosporine, the mean Cmax was increased
by 1.16-fold and the AUClast was increased by 1.19-fold
with simeprevir coadministration in comparison with
cyclosporine alone (Table 3). For tacrolimus, the mean
Cmax was decreased by 24 % and the mean AUClast was
decreased by 17 % with simeprevir coadministration in
comparison with tacrolimus alone. The study was not
designed to investigate the effect of immunosuppressants
on simeprevir. Preliminary data on the effect of immuno-
suppressants on simeprevir are available from an ongoing
phase II study (see Sect. 4.4).
3.1.1.4 Escitalopram Escitalopram is a selective sero-
tonin reuptake inhibitor used to treat depression. Patients
receiving PegIFN-based treatment for HCV experience
high rates of depression [33]; therefore, antidepressants are
often used in this patient population. Escitalopram is
metabolized by CYP3A, CYP2D6 and CYP2C19 [34].
Drug–drug interactions between escitalopram and
simeprevir were evaluated in 20 healthy male subjects in a
randomized, open-label, three-period crossover study with
washout periods of at least 10 days between study periods
[35]. Subjects received simeprevir (150 mg once daily),
escitalopram (10 mg once daily) or simeprevir (150 mg
once daily) plus escitalopram (10 mg once daily) for
7 days; all treatments were given under fed conditions [11].
Pharmacokinetic parameters for escitalopram were
unchanged with coadministration in comparison with esc-
italopram alone (Table 3). Overall, the decrease in
simeprevir exposure seen with escitalopram exposure is not
clinically relevant, and these medications can be adminis-
tered concomitantly without dose adjustment.









Erythromycin : : Coadministration not recommended
Rifampin ; $ Coadministration not recommended
Escitalopram ; $ No dose adjustments needed for either drug
Ritonavir : : Coadministration not recommended
Darunavir NA : No comment
Darunavir/
ritonavirc
: NA Coadministration not recommended
Efavirenz ; $ Coadministration not recommended
Rilpivirine $ $ No dose adjustments needed for either drug
Tenofovir ; $ No dose adjustments needed for either drug
Raltegravir $ : No dose adjustments needed for either drug
Atorvastatin $ : Use the lowest necessary dose of atorvastatin, but do not exceed a daily dose of
40 mg when it is coadministered with simeprevir
Simvastatin $ : Titrate the simvastatin dose carefully and use the lowest necessary dose of it while
monitoring for safety when it is coadministered with simeprevir
AUC24h area under the concentration-time curve from 0 to 24 h, CI confidence interval, NA not applicable
a Summary of data contained in Tables 2 and 3
b The arrows signify the effects on the PK of the indicated drug according to the change in the mean ratio of the AUC24h: an increase (:),
decrease (;) or no change ($; if the 90 % CI is within the range of 0.80–1.25)
c The dose of simeprevir was 150 mg once daily when it was administered alone, compared with 50 mg when it was coadministered with
darunavir/ritonavir
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3.1.1.5 Methadone Methadone is a synthetic narcotic
analgesic used to treat opioid dependence. Because intra-
venous drug use is a common mode of transmission of
HCV infection [36], patients with HCV may receive
maintenance methadone therapy. Methadone exists as a
racemic mixture of R(-) and S(?) enantiomers, with R(-)
responsible for most of the therapeutic effect [37]. The
metabolism of methadone is not completely understood;
however, CYP enzymes (including CYP3A and CYP2D6)
likely contribute to it [38]. In an open-label study, 12 HCV-
negative, opioid-dependent subjects (ten male) receiving
stable methadone maintenance therapy (between 30 and
150 mg once daily) received simeprevir 150 mg once daily
for 7 days [39]. Simeprevir exposure alone could not be
measured in this study for comparison. However, the Cmax
and AUC24h of simeprevir with coadministration of
methadone for 7 days (966 ng/mL and 12,110 ngh/mL,
respectively) were lower than the mean Cmax and AUC24h
reported in a pooled analysis of phase I data in which
simeprevir 150 mg was administered alone once daily for
7 days (1992 and 22,850 ng/mL); the difference in
simeprevir exposure was not considered clinically relevant.
The Cmin, Cmax and AUC24h of both methadone enan-
tiomers were unchanged with coadministration of
simeprevir in comparison with methadone alone (Table 3).
Simeprevir and methadone may be administered simulta-
neously without dose adjustment.
3.1.1.6 Daclatasvir Daclatasvir, an NS5A replication
complex inhibitor, was developed for the treatment of
chronic HCV infection (approved in Europe) [40]. It is a
CYP3A substrate and an inhibitor of P-gp, OATP1B1 and
BCRP [40]. Drug–drug interactions with simeprevir were
evaluated in a two-panel, randomized, open-label, two-
period crossover study with a washout period of 7 days
between study periods. Nineteen healthy subjects (18 male)
received daclatasvir (60 mg once daily) or daclatasvir
(60 mg once daily) plus simeprevir (150 mg once daily)
for 7 days, and 25 healthy subjects (20 male) received
simeprevir (150 mg once daily) or simeprevir (150 mg
once daily) plus daclatasvir (60 mg once daily) for 7 days;
all treatments were administered under fed conditions (data
on file). The mean Cmax and AUC24h of daclatasvir were
increased by 1.50- and 1.96-fold, respectively, with coad-
ministration in comparison with daclatasvir alone. The
mean Cmax and AUC24h of simeprevir were increased by
1.39- and 1.44-fold, respectively. No dose adjustment of
daclatasvir or simeprevir is required [40].
3.1.2 Drugs Metabolized by Glucuronidation
3.1.2.1 Raltegravir Raltegravir, an HIV integrase inhi-
bitor, which is cleared via glucuronidation using uridine
diphosphate glucuronosyltransferase (UGT) 1A1, is indi-
cated for the treatment of HIV infection. Drug–drug
interactions were evaluated in a randomized, open-label,
three-period crossover study with a washout period of at
least 14 days [41]. Twenty-four healthy subjects (17 male)
received simeprevir (150 mg once daily), raltegravir
(400 mg twice daily) or simeprevir (150 mg once daily)
plus raltegravir (400 mg twice daily) for 7 days under fed
conditions. Coadministration resulted in no clinically rel-
evant difference in simeprevir or raltegravir exposure
(although the 90 % CI for the AUC24h ratio of test to ref-
erence for simeprevir did not include 1; see Tables 2 and




Sofosbuvir, an HCV nucleotide analogue NS5B poly-
merase inhibitor, is indicated for the treatment of HCV
infection [22]. Sofosbuvir is a substrate for CatA and car-
boxylesterase (CES) 1; these enzymes aid in the rapid
conversion of[90 % of sofosbuvir to its active metabolite
GS-331007 [42]. Sofosbuvir (the parent compound) is also
a substrate of BCRP and P-gp. Drug–drug interactions with
simeprevir were evaluated in a phase II, randomized, open-
label study (the COSMOS study) of HCV treatment-
experienced and treatment-naı¨ve subjects (data on file).
Subjects received simeprevir (150 mg once daily under fed
conditions) and sofosbuvir (400 mg once daily) alone or in
combination with RBV. An analysis of serial pharma-
cokinetic samples obtained from 22 subjects (10 male)
demonstrated no clinically significant effect of sofosbuvir
on simeprevir exposure. In comparison with another study
in which sofosbuvir was administered in the absence of
simeprevir, the sofosbuvir Cmax and AUC24h were
increased by 1.19- and 3.16-fold, respectively; the Cmax of
the major metabolite of sofosbuvir, GS-331007, was
decreased 31 %, and the AUC24h was unaffected. The
increases in sofosbuvir exposure were not considered
clinically relevant because of the low transient exposure to
this form of the drug relative to the total drug-related
material. Simeprevir and sofosbuvir may be coadminis-
tered without dose adjustment.
4 Simeprevir as a Substrate of Metabolic Drug–
Drug Interactions
Given that simeprevir is primarily metabolized by CYP3A,
drugs that induce or inhibit the CYP3A enzyme may
decrease or increase simeprevir exposure, respectively.
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4.1 CYP3A Inhibitors
4.1.1 Ritonavir
Ritonavir, a protease inhibitor used to treat HIV infection,
is a strong CYP3A inhibitor and an inhibitor of P-gp and
MRP2 [43]. In a phase I, randomized, open-label, two-
period study with a washout period of at least 7 days, 12
healthy male subjects were administered simeprevir
(200 mg once daily on days 1–7) or ritonavir (100 mg
twice daily on days 1–15) plus simeprevir (200 mg once
daily on days 6–12) under fed conditions [21]. Simeprevir
exposure was increased after the first dose in the coad-
ministration group, with increases in the Cmax and AUC24h
of 1.30- and 1.83-fold, respectively, in comparison with
simeprevir alone. Simeprevir exposure was further
increased in subjects who received multiple doses of
simeprevir and ritonavir, with increases in the Cmax,
AUC24h and Cmin of 4.70-, 7.18- and 14.35-fold, respec-
tively, in comparison with administration of simeprevir
alone. Given the increase in simeprevir exposure, coad-
ministration of simeprevir with ritonavir is not recom-
mended [11].
4.1.2 Darunavir/Ritonavir
The combination of darunavir, a protease inhibitor, with
low-dose ritonavir is used to treat HIV infection [43, 44].
Interactions between darunavir/ritonavir and simeprevir
were evaluated in a phase I, randomized, open-label, three-
period crossover study with a washout period of at least
7 days [41]. Healthy subjects [n = 25 (13 male)] received
simeprevir (150 mg once daily), darunavir/ritonavir (800/
100 mg once daily) or simeprevir (50 mg once daily) plus
darunavir/ritonavir (800/100 mg once daily) for 7 days
[41]. A lower dose of simeprevir (50 mg once daily) was
used in the simeprevir/darunavir/ritonavir coadministration
group because of the increased simeprevir exposure seen
with coadministration of simeprevir and ritonavir alone
[21]. There was increased exposure to simeprevir with
coadministration in spite of the dose-reduction of
simeprevir to 50 mg. The Cmax and AUC24h were 1.79- and
2.59-fold higher, respectively, in comparison with admin-
istration of 150 mg simeprevir alone (Table 2) [41]. For
darunavir, the Cmax and AUC24h were unaffected by
coadministration (the Cmin was increased by 1.31-fold;
however, the 90 % CIs for the darunavir Cmin and AUC24h
did not include 1; Table 3). For ritonavir, the Cmax and
AUC24h were increased by 1.23- and 1.32-fold, respec-
tively, with coadministration in comparison with ritonavir
alone. Given the significant increase in simeprevir expo-
sure, despite dose adjustment, coadministration of
simeprevir and darunavir/ritonavir is not recommended.
4.1.3 Erythromycin
The macrolide antibiotic erythromycin is both a moderate
CYP3A inhibitor and a P-gp inhibitor [43]. In a phase I,
randomized, open-label, three-period crossover study with
a washout period of at least 10 days, 24 healthy subjects
(eight male) were administered simeprevir (150 mg once
daily on days 1–7), erythromycin (500 mg three times daily
on days 1–6; 500 mg single dose on day 7) or simeprevir
(150 mg once daily on days 1–7) plus erythromycin
(500 mg three times daily on days 1–7) under fed condi-
tions [11, 45]. For simeprevir, coadministration with ery-
thromycin increased the mean AUC24h, Cmax and Cmin by
7.47-, 4.53- and 12.74-fold, respectively, in comparison
with simeprevir alone (Table 2). For erythromycin, coad-
ministration with simeprevir increased the mean AUC from
0 to 8 h (AUC8h) by 1.90-fold and increased the Cmax and
Cmin by 1.59- and 3.08-fold, respectively, in comparison
with administration of erythromycin alone (Table 3).
Given the increased exposure to both drugs, coadminis-




Rifampin is an antituberculosis agent used to treat infec-
tions with Mycobacterium tuberculosis. It is a CYP3A
and P-gp inducer and an inhibitor of OATP1B [46, 47].
Drug–drug interactions with simeprevir were evaluated in a
phase I, randomized, open-label, three-period crossover study
with a washout period of at least 10 days [21]. Healthy
subjects (n = 21; 20 male and one female) received
simeprevir (200 mg once daily), rifampin (600 mg once
daily) or simeprevir (200 mg once daily) plus rifampin
(600 mg once daily; when coadministered, they were given
in a fasting state) for 7 days [11]. For simeprevir, coad-
ministration decreased the mean Cmin and AUC24h by 92
and 48 %, respectively, and increased the Cmax by 1.31-
fold in comparison with simeprevir alone; the increase in
the Cmax was likely due to OATP1B inhibition (Table 2).
Coadministration did not affect rifampin exposure
(Table 3). Simeprevir and rifampin should not be coad-
ministered, as the resultant decrease in simeprevir exposure
may result in reduced therapeutic effect of simeprevir.
4.2.2 Efavirenz
Efavirenz, an NNRTI used in the treatment of HIV infec-
tion, is a CYP3A and CYP2B6 inducer and an MRP2
inhibitor (MRP2 inhibition based on in vitro data) [48, 49].
Interactions between simeprevir and efavirenz were
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evaluated in a phase I, open-label, randomized, three-pe-
riod crossover study with a washout period of at least
14 days [41]. Twenty-four healthy subjects (13 male)
received simeprevir (150 mg once daily), efavirenz
(600 mg once daily) or simeprevir (150 mg once daily)
plus efavirenz (600 mg once daily) for 14 days; efavirenz
was given 2 h postprandially. For simeprevir, coadminis-
tration resulted in a 71 % decrease in exposure (the AUC)
in comparison with simeprevir alone (Table 2). There was
no change in efavirenz exposure with coadministration
(Table 3). Coadministration of simeprevir and efavirenz is
not recommended, as it may result in a reduced therapeutic
effect of simeprevir.
4.3 Transporter Interactions
Simeprevir is a substrate of the hepatic uptake transporter
OATP and of several efflux transporters, including MRP2,
P-gp and BRCP. Drugs that inhibit the OATP, P-gp, MRP2
or BRCP transporters may affect the pharmacokinetics of
simeprevir.
In vitro studies also suggest that simeprevir is an inhi-
bitor of the transporters OATP1B1, OATP1B3, P-gp,
MRP2 and BCRP; it has the potential to alter the phar-
macokinetics of drugs that are substrates for these trans-
porters (data on file) [11, 20]. It is also an in vitro inhibitor
of the bile salt transporters BSEP and sodium taurocholate
cotransporting polypeptide (NTCP; data on file).
4.3.1 Digoxin
Digoxin, a P-gp substrate, is a cardiac glycoside used in the
treatment of mild to moderate heart failure [43]. In a ran-
domized, open-label, two-period crossover study with a
washout period of at least 14 days, 16 healthy subjects (13
male) received digoxin (0.25 mg single dose) or simeprevir
(150 mg once daily for 7 days) plus digoxin (0.25 mg
single dose on day 7) under fed conditions (data on file)
[50]. When digoxin and simeprevir were coadministered,
the mean Cmax and AUC24h of digoxin were increased by
1.31- and 1.39-fold, respectively, in comparison with
administration of digoxin alone (Table 3) [11, 50]. Given
these results, concentrations of digoxin should be moni-
tored and used for titration of the digoxin dose to obtain the
desired clinical effect.
4.3.2 Tenofovir Disoproxil Fumarate
Tenofovir disoproxil fumarate (TDF) is a nucleotide
reverse transcriptase inhibitor (NtRTI) indicated for the
treatment of HIV infection. TDF is taken up by human
organic anion transporter (hOAT) 1 and 3 and MRP4, and
is an inhibitor of MRP2 [49]. TDF interactions with
simeprevir were evaluated in a randomized, open-label,
three-period crossover trial with a washout period of at
least 14 days. Healthy subjects [n = 24 (12 male)]
received simeprevir (150 mg once daily), TDF (300 mg
once daily) or simeprevir (150 mg once daily) plus TDF
(300 mg once daily) for 7 days [41]. In this study, there
was no clinically significant decrease in simeprevir expo-
sure with coadministration (the AUC24h decreased 15 %;
Table 2). Tenofovir exposure was not affected to a relevant
degree (the AUC24h increased by 1.18-fold) with coad-
ministration (Table 3). These results suggest that TDF may
be administered with simeprevir without dose adjustment.
4.3.3 Rosuvastatin
Rosuvastatin is a hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, which is not metabolized
by CYP enzymes; it is a substrate for OATP1B1,
OATP1B3, NTCP and BCRP [51]. Interactions between
rosuvastatin and simeprevir were evaluated in 16 healthy
subjects (10 male) in a randomized, open-label, two-period
crossover study with a washout period of at least 14 days
(data on file) [50]. Subjects received rosuvastatin alone
(10 mg single dose) or simeprevir (150 mg once daily on
days 1–7) plus rosuvastatin (10 mg single dose on day 7)
under fed conditions. With simeprevir coadministration,
the mean Cmax and AUC24h of rosuvastatin were increased
by 3.17- and 2.81-fold, respectively, in comparison with
administration of rosuvastatin alone (Table 3). Like the
other statin drugs, rosuvastatin should be titrated to the
lowest possible dose, with close safety monitoring when it
is used in combination with simeprevir.
4.4 Combined Metabolic and Transporter
Interactions
4.4.1 Atorvastatin and Simvastatin
Atorvastatin and simvastatin are HMG-CoA reductase
inhibitors indicated for cholesterol blood abnormalities, in
conjunction with diet [51, 52]. They are both metabolized
by CYP3A and are substrates of OATP1B. In a random-
ized, open-label, two-panel study, 36 healthy subjects (26
male) received atorvastatin (40 mg single doses on days 1
and 13) plus simeprevir (150 mg once daily on days 4–15)
or simvastatin (40 mg single doses on days 1 and 13) plus
simeprevir (150 mg once daily on days 4–15) under fed
conditions (data on file). There were no clinically relevant
changes in the pharmacokinetics of simeprevir with coad-
ministration of either atorvastatin or simvastatin (Table 2).
However, the Cmax and the AUC from time zero to infinity
(AUC?) of atorvastatin were increased by 1.70- and 2.12-
fold, respectively, with coadministration in comparison
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with atorvastatin administered alone (Table 3) [11]. The
Cmax and AUC? of simvastatin were also increased with
coadministration (by 1.46- and 1.51-fold, respectively) in
comparison with simvastatin alone; the Cmax and AUC? of
its active metabolite, simvastatin acid, were increased by
3.03- and 1.88-fold, respectively (Table 3). Given the
increase in atorvastatin and simvastatin exposure with
simeprevir coadministration, titration of the dose of ator-
vastatin or simvastatin to the lowest possible dose, with
close monitoring, is recommended.
4.4.2 Cyclosporine and Tacrolimus
Cyclosporine is an inhibitor of OATP, P-gp and CYP3A;
mechanistically, an interaction between simeprevir and
cyclosporine may be expected (tacrolimus was also
evaluated in this study; the results are also presented
below) [31]. This is being investigated in an ongoing
phase IIa, open-label, multicentre study in subjects with
recurrent HCV genotype 1b infection following orthotopic
liver transplantation with METAVIR fibrosis scores of
F1–F2, who were on stable immunosuppressive therapy
with cyclosporine [n = 9 (five male)] or tacrolimus
[n = 11 (eight male)] and received simeprevir (150 mg
once daily), daclatasvir (60 mg once daily) or body
weight–based RBV (range 1000–1200 mg daily). A
planned review of interim pharmacokinetic data (from the
day 14 pharmacokinetic analysis) showed increases of
4.7- and 5.8-fold in the Cmax and AUC24h, respectively,
for simeprevir [Cmax 15,321 ng/mL (n = 9); AUC24h
262,618 ngh/mL] in subjects with F1–F2 fibrosis who
were receiving cyclosporine, in comparison with historical
data on simeprevir in the absence of cyclosporine (Cmax
3235 ng/mL; AUC24h 45,202 ngh/mL; data on file).
Therefore, coadministration of simeprevir with cyclos-
porine is not recommended. This interim analysis
demonstrated 79 and 85 % increases in the Cmax and
AUC24h (Cmax 5780 ng/mL; AUC24h 83,808 ngh/mL),
respectively, of simeprevir in subjects receiving
simeprevir plus tacrolimus, in comparison with historical
data on simeprevir alone (data on file). These increases
are not considered clinically significant, and simeprevir
and tacrolimus may be coadministered [11].
5 Theoretical Interactions with Commonly
Coadministered Drugs
On the basis of the mechanisms of drug–drug interactions
described previously, no interactions would be expected
with a number of diabetes medications (metformin, gly-
buride, glitazones, canagliflozin, insulin), antihypertensives
(diuretics, beta-blockers, angiotensin receptor blockers),
cardiovascular medications (nitrates, aspirin, clopidogrel,
rivaroxaban), antipsychotics or HIV medications (dolute-
gravir) [50].
6 Conclusions
Simeprevir is metabolized by the CYP system, largely by
hepatic CYP3A. Therefore, moderate and strong CYP3A
inhibitors, such as ritonavir and erythromycin, may
increase plasma concentrations of simeprevir; thus, coad-
ministration is not recommended. Additionally, moderate
to strong CYP3A inducers, such as efavirenz, may result in
reduced levels of simeprevir and therefore decreased effi-
cacy; thus, coadministration is not recommended.
Simeprevir is also a substrate of the OATP, MRP2, P-gp
and BCRP transporters. Cyclosporine is an inhibitor of
OATP1B1/3, BCRP and P-gp, and is a mild inhibitor of
CYP3A, which causes a significant increase in simeprevir
exposure with coadministration; thus, coadministration is
not recommended.
Simeprevir has mild inhibitory effects on the CYP
metabolic enzymes, including mild inhibition of intestinal
CYP3A and CYP1A2. This was demonstrated by mild
increases in the exposure to oral midazolam (31 %) and
caffeine (12 %) with coadministration of simeprevir, in
comparison with administration of midazolam and caffeine
alone. Simeprevir does not have a clinically relevant effect
on several other drugs metabolized by CYP enzymes,
including tacrolimus.
Simeprevir is an inhibitor of the efflux transporter P-gp,
resulting in an increase in digoxin concentrations when
these drugs are coadministered. Simeprevir is also an
inhibitor of the hepatic uptake transporters OATP1B1/3
and BCRP, which results in increased exposure to rosu-
vastatin, atorvastatin and simvastatin. Therefore, drugs
such as statins (atorvastatin, simvastatin, rosuvastatin) and
digoxin may be administered with dose titration and
or/close monitoring.
Studies have demonstrated that simeprevir can be used
safely and effectively, without dose adjustment, with a
wide variety of medications, such as the NNRTI rilpivirine,
NtRTIs (TDF), integrase inhibitors (raltegravir), oral con-
traceptives (ethinylestradiol, norethindrone), omeprazole,
dextromethorphan and escitalopram.
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